Teligent Receives Fourth FDA Approval on 2017

Teligent (NASDAQ:TLGT) received approval from the US Food and Drug Administration for Clobetasol Propionate Cream USP, 0.05 percent, Emollient.

As quoted in the press release:

This is Teligent’s fourth approval for 2017, and its fifteenth approval from its internally-developed pipeline of topical generic pharmaceutical medicines.

Based on recent QuintilesIMS Health data from June 2017, the total addressable market for this product is approximately $12.0 million.

“Clobetasol Propionate Cream USP, 0.05%, Emollient is Teligent’s fourth FDA approval in 2017,’’ commented Jason Grenfell-Gardner, President and CEO of the Company. “Teligent now has twenty topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products. We expect to launch this product in the fourth quarter of 2017.”

Click here to read the full press release.

Get the Latest Pharmaceutical Investing Stock Information

Get the latest information about companies associated with Pharmaceutical Investing delivered directly to your inbox.


By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report

Leave a Reply